pertuzumab

Ofatumumab is an anti-CD20 mAb; Arzerra for CLL and Kesimpta for relapsing multiple sclerosis. Its monthly subcutaneous self-injection enables thorough B-cell depletion with significantly superior compliance vs intravenous CD20 alternatives.

Paclitaxel is a Cremophor-free, albumin-bound paclitaxel formulation where paclitaxel is delivered in a suspension of albumin nanoparticles. It is administered as a 30-minute IV infusion without steroid or antihistamine premedication. It eliminates the need for Cremophor EL solvent, thereby removing the ri...

Paliperidone Palmitate is a long-acting injectable (LAI) formulation using nanocrystal technology. It is supplied as prefilled syringes requiring no refrigeration or reconstitution, offering once-monthly (1M) and three-monthly (3M) dosing options for schizophrenia, which significantly improves treatment ad...

Panitumumab is a fully human anti-EGFR mAb for RAS wild-type metastatic colorectal cancer. Its fully human sequence minimizes immunogenicity, with proven survival benefit in FOLFOX combination, representing a key precision therapy option in CRC.

Pegfilgrastim is a PEGylated long-acting G-CSF for chemotherapy-induced neutropenia prophylaxis. Its extended half-life reduces dosing from daily to once per chemotherapy cycle, minimizing treatment delays and serving as the benchmark in oncology supportive care.

Pembrolizumab is an anti-PD-1 mAb with the broadest approved indication portfolio globally. Spanning NSCLC first-line to MSI-H/TMB-H pan-tumor indications, it represents the absolute benchmark in immuno-oncology with an exceptionally high market ceiling.

Pertuzumab, trastuzumab, and hyaluronidase is a subcutaneous fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase. Replacing hours of IV infusion with 15-minute subcutaneous administration, it revolutionizes outpatient convenience and marks a milestone in breast cancer treatment delivery.

Ranibizumab is an anti-VEGF-A Fab fragment for wet AMD and DME. As the gold standard in ophthalmic anti-VEGF therapy, it established the foundation of the retinal disease drug market, with clear biosimilar substitution potential post-patent expiry.

Risankizumab is an anti-IL-23 p19 mAb for psoriasis, Crohn's disease, and ulcerative colitis. With industry-leading PASI 90 response rates and q12w maintenance dosing, it offers exceptional compliance and ranks among the fastest-growing assets in immunology.

Romiplostim is a TPO receptor agonist peptibody for immune thrombocytopenia (ITP). As the standard second-line therapy with long-acting subcutaneous design, it remains effective in splenectomy-refractory patients, leading the hematology niche market.

Secukinumab is an anti-IL-17A mAb and the pathway leader in psoriasis, ankylosing spondylitis, and psoriatic arthritis. With industry-leading long-term PASI 100 clearance rates, it is a mature, high-volume immunology asset with stable market share.

Trastuzumab deruxtecan is a HER2-directed ADC that pioneered therapy for HER2-low breast cancer. The DESTINY program has reshaped global guidelines, with massive cross-tumor potential across breast, gastric, and lung cancers, setting the ADC technology benchmark.